TN2010000155A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number: TN2010000155A1
Authority: TN; Tunisia
Prior art keywords: organic compounds; modulator; parkinson; progression; disease
Prior art date: 2007-10-12

Application number

TN2010000155A

Other languages

English (en)

Inventor

Daniel Umbricht

Mancilla Baltazar Gomez

Fabrizio Gasparini

Paolo Therese Di

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-12

Filing date

2010-04-12

Publication date

2011-11-11

2010-04-12 Application filed by Novartis Ag filed Critical Novartis Ag

2011-11-11 Publication of TN2010000155A1 publication Critical patent/TN2010000155A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)

TN2010000155A 2007-10-12 2010-04-12 Organic compounds TN2010000155A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US97948607P	2007-10-12	2007-10-12
US5033308P	2008-05-05	2008-05-05
PCT/EP2008/063544 WO2009047296A2 (fr)	2007-10-12	2008-10-09	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2010000155A1 true TN2010000155A1 (en)	2011-11-11

Family

ID=40348021

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000155A TN2010000155A1 (en)	2007-10-12	2010-04-12	Organic compounds

Country Status (19)

Country	Link
US (2)	US20100249136A1 (fr)
EP (1)	EP2211859B1 (fr)
JP (2)	JP5743545B2 (fr)
KR (1)	KR101572280B1 (fr)
CN (1)	CN101854935A (fr)
AU (1)	AU2008309621A1 (fr)
BR (1)	BRPI0818560A2 (fr)
CA (1)	CA2701853A1 (fr)
CL (1)	CL2008003006A1 (fr)
IL (1)	IL204954A0 (fr)
MA (1)	MA31798B1 (fr)
MX (1)	MX2010003913A (fr)
NZ (1)	NZ584856A (fr)
RU (1)	RU2508107C2 (fr)
SG (1)	SG185293A1 (fr)
TN (1)	TN2010000155A1 (fr)
TW (1)	TW200924745A (fr)
WO (1)	WO2009047296A2 (fr)
ZA (1)	ZA201002423B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0913642A2 (pt) *	2008-06-30	2015-11-24	Novartis Ag	produtos de combinação
BRPI0917492A8 (pt) *	2008-08-12	2016-07-05	Novartis Ag	processos para preparação de metil éster de ácido 4-oxo-octa-hidro-indol-1-carboxílico e derivados dos mesmos
JP2013505262A (ja) *	2009-09-17	2013-02-14	バンダービルトユニバーシティー	ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法
AU2012223720A1 (en) *	2011-03-03	2013-09-26	Vanderbilt University	6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
BR112013023813A2 (pt)	2011-03-18	2016-12-13	Novartis Ag	combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
GB201204962D0 (en)	2012-03-21	2012-05-02	Addex Pharmaceuticals Sa	Pharmaceutical combination products for parkinsons disease
EP3071568A1 (fr)	2013-11-19	2016-09-28	Vanderbilt University	Composés imidazopyridine et triazolopyridine substitués utilisés comme modulateurs allostériques négatifs de mglur
US9533982B2 (en)	2014-03-20	2017-01-03	Vanderbilt University	Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en)	2014-10-03	2017-01-24	Vanderbilt University	Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
KR101749675B1 (ko) *	2015-07-20	2017-06-26	동국대학교 산학협력단	멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6379666B1 (en) *	1999-02-24	2002-04-30	Edward L. Tobinick	TNF inhibitors for the treatment of neurological, retinal and muscular disorders
DE60022050C5 (de) *	1999-06-02	2007-10-11	NPS Pharmaceuticals, Inc., Salt Lake City	Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
GB0128996D0 (en) *	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
US7105548B2 (en) *	2001-12-18	2006-09-12	Merck & Co., Inc.	Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
US7105533B2 (en) *	2002-09-13	2006-09-12	Merck & Co., Inc.	Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
EP1596808A4 (fr) *	2003-02-07	2007-04-04	Yissum Res Dev Co	Derives d'amide l-dopa et utilisations de ceux-ci
EP1667983A4 (fr) *	2003-09-23	2010-07-21	Merck Sharp & Dohme	Modulateurs pyrazole de recepteurs de glutamate metabotropiques
US20070149547A1 (en) *	2004-02-12	2007-06-28	Celine Bonnefous	Bipyridyl amides as modulators of metabotropic glutamate receptor-5
AU2006222289A1 (en) *	2005-03-04	2006-09-14	F. Hoffmann-La Roche Ag	Pyridine-2-carboxamide derivatives as mG1uR5 antagonists
GB0508319D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0508318D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
TW200801005A (en) *	2005-08-15	2008-01-01	Astrazeneca Ab	Acetylenic piperazines as metabotropic glutamate receptor antagonists
AU2006329007A1 (en) *	2005-12-20	2007-06-28	Novartis Ag	Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
CA2663113A1 (fr) *	2006-09-11	2008-03-20	Novartis Ag	Utilisation de derives de l'acide nicotinique comme modulateurs des recepteurs metabotropes du glutamate
BRPI0913642A2 (pt) *	2008-06-30	2015-11-24	Novartis Ag	produtos de combinação

2008
- 2008-10-09 JP JP2010528396A patent/JP5743545B2/ja not_active Expired - Fee Related
- 2008-10-09 MX MX2010003913A patent/MX2010003913A/es active IP Right Grant
- 2008-10-09 CA CA2701853A patent/CA2701853A1/fr not_active Abandoned
- 2008-10-09 NZ NZ584856A patent/NZ584856A/xx not_active IP Right Cessation
- 2008-10-09 KR KR1020107010331A patent/KR101572280B1/ko not_active Expired - Fee Related
- 2008-10-09 BR BRPI0818560A patent/BRPI0818560A2/pt not_active IP Right Cessation
- 2008-10-09 US US12/682,624 patent/US20100249136A1/en not_active Abandoned
- 2008-10-09 CN CN200880110746A patent/CN101854935A/zh active Pending
- 2008-10-09 WO PCT/EP2008/063544 patent/WO2009047296A2/fr not_active Ceased
- 2008-10-09 TW TW097139070A patent/TW200924745A/zh unknown
- 2008-10-09 RU RU2010118454/15A patent/RU2508107C2/ru not_active IP Right Cessation
- 2008-10-09 AU AU2008309621A patent/AU2008309621A1/en not_active Abandoned
- 2008-10-09 SG SG2012075677A patent/SG185293A1/en unknown
- 2008-10-09 EP EP08805185.9A patent/EP2211859B1/fr not_active Not-in-force
- 2008-10-10 CL CL2008003006A patent/CL2008003006A1/es unknown
2010
- 2010-04-07 ZA ZA2010/02423A patent/ZA201002423B/en unknown
- 2010-04-08 IL IL204954A patent/IL204954A0/en unknown
- 2010-04-12 TN TN2010000155A patent/TN2010000155A1/fr unknown
- 2010-04-30 MA MA32804A patent/MA31798B1/fr unknown
2014
- 2014-08-29 JP JP2014175983A patent/JP2014240425A/ja active Pending
2015
- 2015-06-11 US US14/736,901 patent/US20150272929A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ZA201002423B (en)	2010-12-29
EP2211859A2 (fr)	2010-08-04
JP5743545B2 (ja)	2015-07-01
US20150272929A1 (en)	2015-10-01
SG185293A1 (en)	2012-11-29
CN101854935A (zh)	2010-10-06
WO2009047296A2 (fr)	2009-04-16
NZ584856A (en)	2012-12-21
RU2010118454A (ru)	2011-11-20
JP2014240425A (ja)	2014-12-25
EP2211859B1 (fr)	2016-01-06
CL2008003006A1 (es)	2009-05-08
CA2701853A1 (fr)	2009-04-16
MX2010003913A (es)	2010-04-27
US20100249136A1 (en)	2010-09-30
MA31798B1 (fr)	2010-10-01
WO2009047296A3 (fr)	2009-08-20
IL204954A0 (en)	2010-11-30
RU2508107C2 (ru)	2014-02-27
JP2011500529A (ja)	2011-01-06
AU2008309621A1 (en)	2009-04-16
KR101572280B1 (ko)	2015-11-26
BRPI0818560A2 (pt)	2019-09-24
KR20100088136A (ko)	2010-08-06
TW200924745A (en)	2009-06-16

Publication	Publication Date	Title
TN2010000155A1 (en)	2011-11-11	Organic compounds
MX2009006536A (es)	2009-06-26	Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX2009008347A (es)	2009-10-19	Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
IL195256A0 (en)	2009-08-03	Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2008124660A3 (fr)	2008-11-27	Procédés et compositions pour le traitement du cancer
PH12015500550A1 (en)	2016-06-13	Anti-notch1 nrr antibodies and methods using same
MX2009012625A (es)	2009-12-07	Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2006119329A3 (fr)	2007-11-22	Compositions et procedes pour traiter des maladies neurodegeneratives
MX2009013082A (es)	2010-01-15	Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
TW200738724A (en)	2007-10-16	Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TNSN08400A1 (en)	2010-04-14	Organic compounds and their uses
GB2463833A (en)	2010-03-31	Methods and compositions for the treatment of neurological disorders
MX2007009356A (es)	2007-12-07	Compuestos y composiciones como moduladores de ppar.
WO2010030891A3 (fr)	2010-06-03	Inhibiteurs de f<sb>1</sb>f<sb>0</sb>-atpase à base d’aryle guanidine et procédés associés
MX2009002684A (es)	2009-06-05	Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico.
TNSN08496A1 (en)	2010-04-14	Aminothiazoles and their uses
WO2007050793A3 (fr)	2008-01-24	Methodes et compositions de traitement du syndrome de marfan et de troubles associes
MX2010000956A (es)	2010-03-01	Derivados de isoftalamida que inhiben actividad de beta-secretasa.
MX2009009693A (es)	2009-10-07	Metodos para activar irs-1 y akt.
NL1030418A1 (nl)	2006-05-16	Azabenzoxazolen voor de behandeling van CZS-stoornissen.
TN2009000495A1 (en)	2011-03-31	Macrocycles and their uses
MX2010004463A (es)	2010-05-03	Compuestos de indolina.
WO2009051661A3 (fr)	2009-07-16	Analogues-oxy-alkylamino aryle substitués et utilisations de ceux-ci
WO2008085927A3 (fr)	2008-09-18	Procédés, compositions et kits destinés au traitement de la douleur
WO2008103431A3 (fr)	2009-06-25	Liposomes adni